



C39)



4-[5-(difluoromethyl)-3-phenylisoxazol-4-yl]benzenesulfonamide;

5


C40)



[1,1':2',1''-terphenyl]-4-sulfonamide;


10

C41)



4-(methylsulfonyl)-1,1',2],1''-terphenyl;


C42)



4-(2-phenyl-3-pyridinyl)benzenesulfonamide;

5


C43)



N-(2,3-dihydro-1,1-dioxido-6-phenoxy-1,2-benzisothiazol-5-yl)methanesulfonamide; and

10


C44)



N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]methanesulfonamide;


15

45)



;


46)



;


5

47)



;

48)



10

More preferred COX-2 inhibitors that may be used in the present invention are selected from the group consisting of: